Impact of patient’s V&P on recommendations
| Best strategy for RV range . | Best strategy . | Probability of VTE recurrence . | |||||
|---|---|---|---|---|---|---|---|
| R1 . | R2 . | R3-R5 . | R6 . | ||||
| 0.1 . | 0.01 . | 0.05 . | 0.075 . | ||||
| Bleeding risk | Low risk | 0.005 | Treat none | RV ≥ 19.226 | RV ≥ 1.923 | RV ≥ 9.613 | RV ≥ 14.419 |
| Test | 11.652 ≤ RV ≤ 19.226 | 1.165 ≤ RV ≤ 1.923 | 5.826 ≤ RV ≤ 9.613 | 8.739 ≤ RV ≤ 14.419 | |||
| Treat all | RV ≤ 11.652 | RV ≤ 1.165 | RV ≤ 5.826 | RV ≤ 8.739 | |||
| High risk | 0.015 | Treat none | RV ≥ 6.409 | RV ≥ 0.641 | RV ≥ 3.204 | RV ≥ 4.806 | |
| Test | 3.884 ≤ RV ≤ 6.409 | 0.388 ≤ RV ≤ 0.641 | 1.942 ≤ RV ≤ 3.204 | 2.913 ≤ RV ≤ 4.806 | |||
| Treat all | RV ≤ 3.884 | RV ≤ 0.388 | RV ≤ 1.942 | RV ≤ 2.913 | |||
| Best strategy for RV range . | Best strategy . | Probability of VTE recurrence . | |||||
|---|---|---|---|---|---|---|---|
| R1 . | R2 . | R3-R5 . | R6 . | ||||
| 0.1 . | 0.01 . | 0.05 . | 0.075 . | ||||
| Bleeding risk | Low risk | 0.005 | Treat none | RV ≥ 19.226 | RV ≥ 1.923 | RV ≥ 9.613 | RV ≥ 14.419 |
| Test | 11.652 ≤ RV ≤ 19.226 | 1.165 ≤ RV ≤ 1.923 | 5.826 ≤ RV ≤ 9.613 | 8.739 ≤ RV ≤ 14.419 | |||
| Treat all | RV ≤ 11.652 | RV ≤ 1.165 | RV ≤ 5.826 | RV ≤ 8.739 | |||
| High risk | 0.015 | Treat none | RV ≥ 6.409 | RV ≥ 0.641 | RV ≥ 3.204 | RV ≥ 4.806 | |
| Test | 3.884 ≤ RV ≤ 6.409 | 0.388 ≤ RV ≤ 0.641 | 1.942 ≤ RV ≤ 3.204 | 2.913 ≤ RV ≤ 4.806 | |||
| Treat all | RV ≤ 3.884 | RV ≤ 0.388 | RV ≤ 1.942 | RV ≤ 2.913 | |||
RV (relative values) refers to patients’ V&P; when RV < 1, the patient values avoiding outcomes of disease more than avoiding treatment harms; if RV > 1, the patient places more importance on avoiding the harms of treatment than on the consequences of the disease. When the patient is indifferent between treatment harms and the consequences of the disease outcome, RV is 1. When RV is 1, the thresholds are solely determined by empirical evidence (see Method section for details).